Wednesday, June 10, 2026

biotech Β· PTSD - Post Traumatic Stress Disorder Β· P1b: Advanced Solid Tumors Β· CMPX

Compass Therapeutics

Compass Therapeutics clinical programs β€” 3 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

80 Guest Street, Suite 601, Boston, MA 02135, US HQ
2014 Founded
54 Employees
Public company Type
CMPX Β· NYSE Ticker
Company details
Status
Public
HQ
80 Guest Street, Suite 601, Boston, MA 02135, US
Founded
2014
Employees
54
Programs
15
Drugs
3
Patents
100
Intelligence Β· Clinical Programs

Compass Therapeutics projects

3 ClinicalTrials.gov programs sponsored by Compass Therapeutics.

Compass Therapeutics has 3 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. CTX-10726

    Compass Therapeutics

    Gastroesophageal Cancer (GC)

    phase 1 small molecule active

    1 trial
  2. CTX-471

    Compass Therapeutics

    Locally Advanced Solid Tumor

    phase 1 small molecule completed

    1 trial
  3. CTX-8371

    Compass Therapeutics

    Non Small Cell Lung Cancer

    phase 1 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Compass Therapeutics have?

3 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.